128 related articles for article (PubMed ID: 19088531)
1. Systemic lupus erythematosus associated with paclitaxel use in the treatment of ovarian cancer.
Dasanu CA; Alexandrescu DT
South Med J; 2008 Nov; 101(11):1161-2. PubMed ID: 19088531
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody.
Adachi A; Horikawa T
J Dermatol; 2007 Jul; 34(7):473-6. PubMed ID: 17584326
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel: friend or foe for systemic lupus erythematosus?
Pan HF; Wu GC; Li XP; Ye DQ
South Med J; 2009 May; 102(5):554-5. PubMed ID: 19373161
[No Abstract] [Full Text] [Related]
4. [Paclitaxel-induced lupus].
Lortholary A; Cary-Ten Have Dallinga M; El Kouri C; Morineau N; Ramée JF
Presse Med; 2007 Sep; 36(9 Pt 1):1207-8. PubMed ID: 17521858
[TBL] [Abstract][Full Text] [Related]
5. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer.
De Angelis R; Bugatti L; Cerioni A; Del Medico P; Filosa G
Clin Rheumatol; 2003 Feb; 22(1):49-52. PubMed ID: 12605319
[TBL] [Abstract][Full Text] [Related]
6. Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients.
Lehoczky O; Bagaméri A; Udvary J; Pulay T
J Obstet Gynaecol; 2002 May; 22(3):312-3. PubMed ID: 12521509
[No Abstract] [Full Text] [Related]
7. Paclitaxel and docetaxel in breast and ovarian cancer.
Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
[TBL] [Abstract][Full Text] [Related]
8. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel-induced myocardial infarction in a case of carcinoma ovary.
Londhey VA; Parikh FS
J Assoc Physicians India; 2009 Apr; 57():342-3. PubMed ID: 19702043
[No Abstract] [Full Text] [Related]
10. [Taxol in the treatment of ovarian neoplasm].
Wang Y; Huang R; Huang H
Zhonghua Fu Chan Ke Za Zhi; 1999 Jul; 34(7):439-41. PubMed ID: 11360659
[No Abstract] [Full Text] [Related]
11. Use of chemotherapy for ovarian cancer during human pregnancy: case report and literature review.
Mantovani G; Gramignano G; Mais V; Melis GB; Parodo G; Carrucciu GM
Eur J Obstet Gynecol Reprod Biol; 2007 Apr; 131(2):238-9. PubMed ID: 16698170
[No Abstract] [Full Text] [Related]
12. [Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].
Borovik R; Steiner M; Atad J; Sneiderman B; Rosenberg T; Palti S
Harefuah; 1998 Apr; 134(8):605-8, 671. PubMed ID: 10911422
[TBL] [Abstract][Full Text] [Related]
13. Photodistributed erythema multiforme: paclitaxel-related, photosensitive conditions in patients with cancer.
Cohen PR
J Drugs Dermatol; 2009 Jan; 8(1):61-4. PubMed ID: 19180897
[TBL] [Abstract][Full Text] [Related]
14. Platelet-sparing effect of paclitaxel in heavily pretreated ovarian cancer patients.
Ishikawa H; Fujiwara K; Suzuki S; Tanaka Y; Kohno I
Int J Clin Oncol; 2002 Oct; 7(5):330-3. PubMed ID: 12402070
[TBL] [Abstract][Full Text] [Related]
15. [Taxol].
Kühnle H
Zentralbl Gynakol; 1996; 118(10):580. PubMed ID: 8999717
[No Abstract] [Full Text] [Related]
16. Emergency. Chemotherapy-induced hypersensitivity reaction.
Myers JS; Kearney K
Am J Nurs; 2000 Apr; 100(4):53-4. PubMed ID: 10776352
[No Abstract] [Full Text] [Related]
17. GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients.
Bergmann TK; Vach W; Feddersen S; Eckhoff L; Gréen H; Herrstedt J; Brosen K
Acta Oncol; 2013 May; 52(4):871-4. PubMed ID: 22877241
[No Abstract] [Full Text] [Related]
18. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
[TBL] [Abstract][Full Text] [Related]
19. Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis.
Lombardi G; Nicoletto MO; Gusella M; Fiduccia P; Dalla Palma M; Zuin A; Fiore D; Donach M; Zagonel V
Cancer Chemother Pharmacol; 2012 Mar; 69(3):781-7. PubMed ID: 22037881
[TBL] [Abstract][Full Text] [Related]
20. Eosinophilic ascites: taxol-induced hypersensitivity?
Kobayashi TK; Muramatsu M; Ueda M; Nishino T; Bamba M; Urabe M; Moritani S
Cytopathology; 2004 Jun; 15(3):171-2. PubMed ID: 15165278
[No Abstract] [Full Text] [Related]
[Next] [New Search]
